secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-006997
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd reports preliminary Q4 2025 revenue $17.2M, VYD2311 Phase 3 trial initiated, top-line data mid-2026
--------------------------------------------------------------------------------

- Preliminary Q4 2025 PEMGARDA net product revenue of $17.2M, up 25% YoY from $13.8M and 31% QoQ from $13.1M.
- Ending 2025 cash and cash equivalents of $226.7M after raising over $200M in 2H 2025.
- Initiated DECLARATION Phase 3 pivotal trial of VYD2311 for COVID prevention; top-line data expected mid-2026.
- Fast Track designation for VYD2311 granted by FDA in December 2025.
- Selected potential best-in-class RSV antibody candidate VBY329; IND readiness targeted for 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526006997/0001193125-26-006997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526006997/d93103d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer